产品资料
  首页 >>> 产品目录 >>> **学 >>> 一抗

Phospho-FAK (Tyr397)抗体

如果您对该产品感兴趣的话,可以
产品名称: Phospho-FAK (Tyr397)抗体
产品型号:
产品展商: XYbscience
产品文档: 无相关文档

简单介绍

Phospho-FAK (Tyr397)抗体非受体蛋白酪氨酸激酶与细胞运动、增殖和凋亡相关的信号通路。通过酪氨酸酶的作用来激活由细胞粘附或抗体交叉连接引起的整合,或通过g-蛋白偶联受体(GPCR)等配体,如bombesin或lysophatidic酸,或通过LDL受体占用。Phospho-FAK (Tyr397)抗体在致癌转化中发挥潜在作用,从而增加激酶活性。


Phospho-FAK (Tyr397)抗体  的详细介绍

Phospho-FAK (Tyr397)抗体特异性结合抗原:抗体本身不能直接溶解或杀伤带有特异抗原的靶细胞,通常需要补体或吞噬细胞等共同发挥效应以**病原微生物或导致病理损伤。然而,抗体可通过与病毒或**的特异性结合,直接发挥中和病毒的作用。

产品编号xy- 3159R

英文名称Phospho-FAK (Tyr397)

中文名称磷酸化粘着斑激酶抗体

别    名FAK (phospho Y397); p-FAK (phospho Y397); PTK2(phospho Y397); p-PTK2; FADK 1; FADK; FAK 1; FAK related non kinase polypeptide; FAK1; Focal adhesion kinase 1; FRNK; pp125FAK; Protein tyrosine kinase 2; Protein Tyrosine Kinase Cytoplasmic; PTK 2; FAK1_HUMAN; Focal adhesion kinase-related nonkinase; Protein phosphatase 1 regulatory subunit 71; PPP1R71; Protein-tyrosine kinase 2; p125FAK.  

说 明 书100ul  

产品类型磷酸化抗体

研究领域肿瘤  **学  转录调节因子  激酶和磷酸酶  

抗体来源Rabbit

克隆类型Polyclonal

Phospho-FAK (Tyr397)抗体交叉反应 Human, Mouse, Rat, Chicken, Dog, Cow, Horse, Rabbit,

产品应用WB=1:500-2000 ELISA=1:500-1000 IHC-P=1:400-800 IHC-F=1:400-800 Flow-Cyt=1μg /Test IF=1:100-500 (石蜡切片需做抗原修复)

not yet tested in other applications.

optimal dilutions/concentrations should be determined by the end user.

分 子 量116kDa

细胞定位细胞核 细胞浆 细胞膜

性    状Lyophilized or Liquid

浓    度1mg/1ml

免 疫 原KLH cunjugated Synthesised phosphopeptide derived from human FAK 1 around the phosphorylation site of Tyr397:DD(p-Y)AE

亚    型IgG

纯化方法affinity purified by Protein A

储 存 液0.01M TBS(pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol.

Phospho-FAK (Tyr397)抗体保存条件Store at -20 °C for one year. Avoid repeated freeze/thaw cycles. The lyophilized antibody is stable at room temperature for at least one month and for greater than a year when kept at -20°C. When reconstituted in sterile pH 7.4 0.01M PBS or diluent of antibody the antibody is stable for at least two weeks at 2-4 °C.

PubMedPubMed

产品介绍background:

Non-receptor protein-tyrosine kinase implicated in signaling pathways involved in cell motility, proliferation and apoptosis. Activated by tyrosine-phosphorylation in response to either integrin clustering induced by cell adhesion or antibody cross-linking, or via G-protein coupled receptor (GPCR) occupancy by ligands such as bombesin or lysophosphatidic acid, or via LDL receptor occupancy. Plays a potential role in oncogenic transformations resulting in increased kinase activity.


Function:

Non-receptor protein-tyrosine kinase implicated in signaling pathways involved in cell motility, proliferation and apoptosis. Activated by tyrosine-phosphorylation in response to either integrin clustering induced by cell adhesion or antibody cross-linking, or via G-protein coupled receptor (GPCR) occupancy by ligands such as bombesin or lysophosphatidic acid, or via LDL receptor occupancy. Microtubule-induced dephosphorylation at Tyr-397 is crucial for the induction of focal adhesion disassembly. Plays a potential role in oncogenic transformations resulting in increased kinase activity.


Subunit:

Interacts (via first Pro-rich region) with CAS family members (via SH3 domain), including BCAR1, BCAR3, CASS4 and NEDD9. Interacts with GIT1. Interacts with SORBS1. Interacts with RGNEF. Interacts with SHB. Interacts with PXN and TLN1. Interacts with STAT1. Interacts with DCC. Interacts with WASL. Interacts with ARHGEF7. Interacts with GRB2 and GRB7 (By similarity). Component of a complex that contains at least FER, CTTN and PTK2/FAK1. Interacts with BMX. Interacts with TGFB1I1. Interacts with STEAP4. Interacts with ZFYVE21. Interacts with ESR1. Interacts with PIK3R1 or PIK3R2. Interacts with SRC, FGR, FLT4 and RET. Interacts with EPHA2 in resting cells; activation of EPHA2 recruits PTPN11, leading to dephosphorylation of PTK2/FAK1 and dissociation of the complex. Interacts with EPHA1 (kinase activity-dependent). Interacts with CD4; this interaction requires the presence of HIV-1 gp120. Interacts with PIAS1. Interacts with ARHGAP26 and SHC1. Interacts with RB1CC1; this inhibits PTK2/FAK1 activity and activation of downstream signaling pathways. Interacts with P53/TP53 and MDM2. Interacts with LPXN (via LD motif 3).


Subcellular Location:

Cell junction, focal adhesion. Cell membrane; Peripheral membrane protein; Cytoplasmic side. Cytoplasm, cell cortex. Cytoplasm, cytoskeleton. Cytoplasm, cytoskeleton, centrosome. Nucleus. Note=Constituent of focal adhesions. Detected at microtubules.


Tissue Specificity:

Detected in B and T lymphocytes. Isoform 1 and isoform 6 are detected in lung fibroblasts (at protein level). Ubiquitous.


Post-translational modifications:

Phosphorylated on tyrosine residues upon activation, e.g. upon integrin signaling. Tyr-397 is the major autophosphorylation site, but other kinases can also phosphorylate this residue. Phosphorylation at Tyr-397 promotes interaction with SRC and SRC family members, leading to phosphorylation at Tyr-576, Tyr-577 and at additional tyrosine residues. FGR promotes phosphorylation at Tyr-397 and Tyr-576. FER promotes phosphorylation at Tyr-577, Tyr-861 and Tyr-925, even when cells are not adherent. Tyr-397, Tyr-576 and Ser-722 are phosphorylated only when cells are adherent. Phosphorylation at Tyr-397 is important for interaction with BMX, PIK3R1 and SHC1. Phosphorylation at Tyr-925 is important for interaction with GRB2. Dephosphorylated by PTPN11; PTPN11 is recruited to PTK2 via EPHA2 (tyrosine phosphorylated). Microtubule-induced dephosphorylation at Tyr-397 is crucial for the induction of focal adhesion disassembly; this dephosphorylation could be catalyzed by PTPN11 and regulated by ZFYVE21.

Sumoylated; this enhances autophosphorylation.


DISEASE:

Note=Aberrant PTK2/FAK1 expression may play a role in cancer cell proliferation, migration and invasion, in tumor formation and metastasis. PTK2/FAK1 overexpression is seen in many types of cancer.


Similarity:

Belongs to the protein kinase superfamily. Tyr protein kinase family.

FAK subfamily.

Contains 1 FERM domain.



SWISS:

Q05397


Gene ID:

5747


Phospho-FAK (Tyr397)抗体antibody, Ab)是由效应B细胞(效应**B细胞)分泌,机体用于抵御外来物质,如病毒,**等抗原,结构呈“Y”字型的球状蛋白质,仅仅存在于脊椎动物的血液和B**细胞膜表面。凡是能够跟抗体结合的物质,均被称作抗原,因此对于抗抗体(能够结合抗体的抗体)来说,抗体本身也是一种抗原物质。

   QQ图片20171030091318

Phospho-FAK (Tyr397)抗体普通抗体重链和轻链的结构

重链结构:普通的**球蛋白具有2条重链(H链),分子量约为50kD,有μ、δ、γ、ε和α五种重链亚型,对应的**球蛋白名称分别为IgMIgGIgAIgDIgE

轻链结构:  普通**球蛋白具有2条轻链(L链),分子质量约25kDa,有κ链和λ链两种亚型,这两种轻链决定了Ig的亚型类别(IgG1IgG2IgG3IgG4)。一个天然的Ig分子两条轻链总是相同的,但在同一个体内可存在分别带有κ或λ链的抗体分子。不同种属生物体内两型轻链的比例不同,正常人血清**球蛋白κ链:λ链约为21,而在小鼠的比例为201

2.2抗体Fab段和Fc

IgG经木瓜蛋白酶酶切后裂解为2个完全相同的Fab段和1Fc,每个Fab段都为单价,可与抗原结合但不会再发生凝集反应;经胃蛋白酶酶切后裂解为1个完整F(ab)2片段和碎片化的Fc片段,F(ab)2片段为双价,可同时结合两个抗原表位。Fab段为抗原结合片段(fragment of antigen bindingFab),相当于抗体分子的两个臂,由一个完整的轻链和重链的VHCH1结构域组成。Fc段为可结晶段(fragment crystallizableFc)相当于IgCH2CH3结构域,是Ig与效应分子或者细胞相互作用的部位。Fab段包含完整的可变区,以及恒定区的CH1区域。Fc段仅指Ig恒定区CH2CH3的区域,相当于Y字结构下面那一部分。

合格 phospho-PP2A alpha+beta(Tyr307) 磷酸化蛋白磷酸酶2A(PP2Aα)抗体
合格 ICBP90/UHRF1 核蛋白95抗体
合格 PPP4C 丝氨酸/苏氨酸蛋白磷酸酶4C抗体
合格 ZnT-1 锌转运蛋白1抗体
合格 NPD014 1号染色体开放阅读框63抗体
合格 CRABP1/Retinol binding protein 视黄醇结合蛋白抗体
合格 合格 SOX10 转录因子SOX10抗体
合格 合格 Phospho-Paxillin(Ser83) 磷酸化桩蛋白Paxillin抗体
合格 合格 caspase-8 subunit p18 半胱氨酸蛋白酶8抗体
合格 合格 kir 6.1 ATP敏感钾离子通道蛋白抗体
合格 Phospholipase C beta 2 磷酯酶Cβ2抗体
合格 合格 合格 CD95/FAS 载脂蛋白1抗体
合格 CH25H 胆固醇25羟化酶抗体
合格 Testin 肿瘤抑制基因Testin抗体
合格 PAK2 p21激活激酶2抗体
合格 CENPH 着丝粒蛋白H抗体
合格 CKAP4 细胞骨架相关蛋白4抗体
合格 CKMT 酸性线粒体肌酸激酶抗体
合格 EZH1 组蛋白赖氨酸N-甲基EZH1抗体
合格 GCET2 **中心B**细胞相关蛋白2抗体
合格 HOXB2 同源盒蛋白B2抗体
合格 合格 ID1 DNA结合抑制因子1抗体
合格 LOXL2 赖氨酰氧化酶相关蛋白2抗体
合格 OLFM4 抗细胞凋亡蛋白OLFM44抗体
合格 PRSS3 脑胰蛋白酶3抗体
合格 RLBP1L1 视黄醛结合蛋白1抗体
合格 SAMD14 SAMD14抗体
合格 RNASE4 血管生成素核糖核酸酶4抗体(肌萎缩性侧索硬化症蛋白)
合格 FCAR/CD89 **球蛋白A Fc段受体1抗体
合格 APEX2 嘌呤嘧啶核酸内切酶2抗体
合格 BCAT2 支链氨基酸转氨酶2抗体
合格 Bcl3 B细胞**瘤蛋白3抗体
合格 合格 NPHS2/Podocin 肾小球裂孔膜蛋白PDCN抗体
合格 Cofilin 肌动蛋白结合蛋白CFL抗体
合格 HSD17B1 羟类固醇脱氢酶17β抗体
合格 BMP15 骨形态发生蛋白15抗体
合格 合格 GATA2 GATA结合蛋白2抗体
合格 GAT1/GABA Transporter 1 γ氨基丁酸运载蛋白1抗体
 


产品留言
标题
联系人
联系电话
内容
验证码
点击换一张
注:1.可以使用快捷键Alt+S或Ctrl+Enter发送信息!
2.如有必要,请您留下您的详细联系方式!